Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wounds and Injuries | 3 | 2021 | 234 | 1.070 |
Why?
|
| Heart Transplantation | 1 | 2022 | 157 | 0.740 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 123 | 0.720 |
Why?
|
| Conservative Treatment | 1 | 2018 | 13 | 0.630 |
Why?
|
| Appendectomy | 1 | 2018 | 48 | 0.620 |
Why?
|
| Intensive Care Units | 3 | 2017 | 445 | 0.610 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 178 | 0.600 |
Why?
|
| Appendicitis | 1 | 2018 | 73 | 0.590 |
Why?
|
| Patient Discharge | 1 | 2021 | 477 | 0.580 |
Why?
|
| Professional-Family Relations | 1 | 2017 | 84 | 0.530 |
Why?
|
| Family | 1 | 2017 | 216 | 0.490 |
Why?
|
| Heart Failure | 1 | 2022 | 859 | 0.480 |
Why?
|
| Patient Care Team | 1 | 2017 | 315 | 0.470 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 245 | 0.460 |
Why?
|
| Injury Severity Score | 2 | 2021 | 103 | 0.370 |
Why?
|
| Blood Component Transfusion | 1 | 2011 | 8 | 0.370 |
Why?
|
| Shock, Hemorrhagic | 1 | 2011 | 19 | 0.370 |
Why?
|
| Resuscitation | 1 | 2011 | 67 | 0.350 |
Why?
|
| Length of Stay | 4 | 2021 | 759 | 0.350 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2015 | 39 | 0.310 |
Why?
|
| Prospective Studies | 4 | 2022 | 3071 | 0.290 |
Why?
|
| Parvovirus B19, Human | 1 | 2004 | 5 | 0.240 |
Why?
|
| Parvoviridae Infections | 1 | 2004 | 23 | 0.240 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2004 | 71 | 0.230 |
Why?
|
| Diseases in Twins | 1 | 2004 | 53 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2004 | 61 | 0.230 |
Why?
|
| Humans | 19 | 2022 | 58820 | 0.230 |
Why?
|
| Patient Handoff | 1 | 2022 | 18 | 0.210 |
Why?
|
| Retrospective Studies | 4 | 2021 | 5921 | 0.200 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 83 | 0.200 |
Why?
|
| Critical Illness | 2 | 2016 | 331 | 0.190 |
Why?
|
| Odds Ratio | 2 | 2021 | 769 | 0.190 |
Why?
|
| Mesenteric Veins | 1 | 2020 | 11 | 0.180 |
Why?
|
| Heart Ventricles | 1 | 2022 | 247 | 0.180 |
Why?
|
| Trauma Centers | 1 | 2021 | 120 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1048 | 0.170 |
Why?
|
| Clostridium Infections | 1 | 2020 | 46 | 0.170 |
Why?
|
| Students, Medical | 1 | 2022 | 234 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 104 | 0.170 |
Why?
|
| General Surgery | 1 | 2022 | 187 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2020 | 139 | 0.160 |
Why?
|
| Young Adult | 4 | 2021 | 4270 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 143 | 0.150 |
Why?
|
| Licensure | 1 | 2016 | 14 | 0.140 |
Why?
|
| Workflow | 1 | 2017 | 58 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 74 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2022 | 5096 | 0.140 |
Why?
|
| Acute Disease | 1 | 2018 | 649 | 0.140 |
Why?
|
| Male | 9 | 2021 | 27258 | 0.130 |
Why?
|
| Wounds, Gunshot | 1 | 2016 | 53 | 0.130 |
Why?
|
| Firearms | 1 | 2016 | 60 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2015 | 15 | 0.130 |
Why?
|
| Interleukin-15 | 1 | 2015 | 21 | 0.130 |
Why?
|
| Brain Edema | 1 | 2015 | 31 | 0.120 |
Why?
|
| Female | 8 | 2021 | 30545 | 0.120 |
Why?
|
| Tissue Adhesions | 1 | 2015 | 20 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2022 | 694 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 148 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2015 | 33 | 0.120 |
Why?
|
| Incidence | 1 | 2018 | 1226 | 0.120 |
Why?
|
| Leukocytes | 1 | 2015 | 107 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 711 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 47 | 0.120 |
Why?
|
| Intestine, Small | 1 | 2015 | 72 | 0.120 |
Why?
|
| Frail Elderly | 1 | 2015 | 110 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2015 | 197 | 0.120 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 170 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2015 | 243 | 0.110 |
Why?
|
| Adult | 5 | 2021 | 15596 | 0.110 |
Why?
|
| Middle Aged | 6 | 2021 | 16117 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2015 | 163 | 0.100 |
Why?
|
| Adolescent | 2 | 2021 | 5862 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 554 | 0.100 |
Why?
|
| Communication | 1 | 2017 | 531 | 0.100 |
Why?
|
| Critical Care | 1 | 2016 | 404 | 0.100 |
Why?
|
| Torque teno virus | 1 | 2011 | 1 | 0.100 |
Why?
|
| Polycythemia Vera | 1 | 2011 | 5 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 737 | 0.100 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 27 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 5045 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 396 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 361 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2015 | 485 | 0.090 |
Why?
|
| Genome, Viral | 1 | 2011 | 120 | 0.090 |
Why?
|
| Cellular Senescence | 1 | 2011 | 103 | 0.090 |
Why?
|
| Cell Division | 1 | 2011 | 440 | 0.090 |
Why?
|
| Quality of Life | 1 | 2015 | 1102 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 1270 | 0.070 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2004 | 5 | 0.060 |
Why?
|
| Fetal Death | 1 | 2004 | 14 | 0.060 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2004 | 43 | 0.060 |
Why?
|
| Aged | 5 | 2020 | 13210 | 0.050 |
Why?
|
| Infant, Premature | 1 | 2004 | 173 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 87 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2004 | 1299 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 298 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 936 | 0.040 |
Why?
|
| Acute Pain | 1 | 2019 | 20 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 540 | 0.040 |
Why?
|
| Analgesics | 1 | 2019 | 100 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 783 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 603 | 0.040 |
Why?
|
| Pregnancy | 1 | 2004 | 2325 | 0.040 |
Why?
|
| Time Factors | 2 | 2015 | 3544 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 1537 | 0.030 |
Why?
|
| Chronic Pain | 1 | 2019 | 142 | 0.030 |
Why?
|
| Traumatology | 1 | 2016 | 8 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 416 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 43 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 173 | 0.030 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2015 | 29 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 43 | 0.030 |
Why?
|
| Mesenteric Ischemia | 1 | 2015 | 5 | 0.030 |
Why?
|
| Naphthalimides | 1 | 2015 | 2 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 6 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 42 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 50 | 0.030 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2015 | 57 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 183 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 64 | 0.030 |
Why?
|
| Cytarabine | 1 | 2015 | 34 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2015 | 21 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 45 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 135 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 170 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 209 | 0.030 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 168 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 279 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2016 | 325 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 161 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2015 | 140 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 170 | 0.030 |
Why?
|
| Palliative Care | 1 | 2015 | 201 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 549 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 667 | 0.020 |
Why?
|
| CD5 Antigens | 1 | 2011 | 18 | 0.020 |
Why?
|
| DNA Virus Infections | 1 | 2011 | 9 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 21 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2011 | 34 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2011 | 32 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2011 | 24 | 0.020 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2011 | 50 | 0.020 |
Why?
|
| Clone Cells | 1 | 2011 | 104 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 191 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 191 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2090 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 1561 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 228 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Kinetics | 1 | 2011 | 728 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 839 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2316 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 692 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1136 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 2875 | 0.020 |
Why?
|
| Child | 1 | 2014 | 4238 | 0.010 |
Why?
|
| United States | 1 | 2016 | 7432 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 10184 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 19483 | 0.010 |
Why?
|